HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

elezanumab

Also Known As:

ABT-555; AE12-1Y-QL

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cui, Yi-Fang: 3 articles (11/2021 - 01/2020)
2.	Huang, Lili: 3 articles (11/2021 - 01/2020)
3.	Mueller, Bernhard K: 3 articles (11/2021 - 01/2020)
4.	Popp, Andreas: 2 articles (11/2021 - 01/2021)
5.	Jacobson, Peer B: 2 articles (01/2021 - 01/2020)
6.	Tator, Charles H: 2 articles (01/2021 - 01/2020)
7.	Bose, Sahana: 1 article (11/2021)
8.	Böser, Preethne: 1 article (11/2021)
9.	Fung, Emma: 1 article (11/2021)
10.	Klein, Corinna: 1 article (11/2021)

Related Diseases

1.	Stroke (Strokes) 06/16/2023 - "In two replicate 28-day pMCAO studies, weekly intravenous infusions of elezanumab, over a range of doses and TTIs of 6 and 24 h after stroke, significantly improved neuromotor function in both pMCAO studies when first administered 6 h after stroke. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/16/2023 - "Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion." 06/16/2023 - "In this preclinical study, we evaluated whether elezanumab, a human anti-RGMa monoclonal antibody, could improve neuromotor function and modulate neuroinflammatory cell activation following AIS with delayed intervention times up to 24 h using a rabbit embolic permanent middle cerebral artery occlusion model (pMCAO). "
3.	Multiple Sclerosis 01/01/2023 - "This study was undertaken to describe the safety, tolerability, pharmacokinetics, and immunogenicity of elezanumab (ABT-555), a fully human monoclonal antibody (mAb) directed against repulsive guidance molecule A (RGMa), in healthy and multiple sclerosis (MS) study participants. " 01/01/2023 - "Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants."
4.	Spinal Cord Injuries (Spinal Cord Injury) 01/01/2021 - "Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates." 01/01/2020 - "Delayed administration of the human anti-RGMa monoclonal antibody elezanumab promotes functional recovery including spontaneous voiding after spinal cord injury in rats."
5.	Neurodegenerative Diseases (Neurodegenerative Disease) 11/01/2021 - "Taken together, these preclinical data demonstrate that elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism, thus providing a compelling rationale for its clinical development in neurodegenerative diseases."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Retinaldehyde (Retinal)
3.	Iron
4.	Cuprizone

Related Therapies and Procedures

1.	Intravenous Infusions